



COMMITMENT TO A CURE

[cellectis.com](https://cellectis.com)



# FORWARD-LOOKING STATEMENTS

---

This presentation contains “forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently available to management.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

The risks and uncertainties include, but are not limited to the risk that the preliminary results from our product candidates will not continue or be repeated, the risk that our clinical trials will not be successful. The risk of not obtaining regulatory approval to commence clinical trials on additional UCART product candidates,

the risk that any one or more of our product candidates will not be successfully developed and commercialized.

Further information on the risk factors that may affect company business and financial performance, is included in our annual report on form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent filings Collectis makes with the Securities and Exchange Commission from time to time.

Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Collectis proprietary information. Not to be copied, distributed or used without Collectis’ prior written consent.

# WRITING THE HISTORY OF ALLOGENEIC CAR T-CELLS

**20 years**

of expertise in  
gene editing

**8 years**

of experience in allogeneic  
CAR-T manufacturing

**6 clinical trials**

ongoing as of 2020;  
3 Cellectis-sponsored  
3 partnered

**INVENTORS / PIONEERS OF GENE EDITING & ALLOGENEIC CAR T-CELLS**



**In 2012 . .**


Mission to develop  
allogeneic CAR T-cells begins

**In 2015 . .**


First-in-man compassionate  
use of an allogeneic CAR-T  
product candidate occurs

# ADVANTAGES OF ALLOGENEIC VS. AUTOLOGOUS CAR-T

## Autologous process:



## Allogeneic process:



# PARTNERSHIPS WITH INDUSTRY LEADERS

Up to \$3.2B in potential milestone payments plus royalties



Exclusive license to 15 allogeneic CAR T-Cell targets including UCARTBCMA / ALLO-715

Up To \$2.8B In Development & Sales Milestones  
+ High Single-Digit Royalties on Sales



Exclusive license to CD19-directed allogeneic CAR T-Cells including UCART19 / ALLO-501 and ALLO-501A<sup>1</sup>

Up To \$410M In Development & Sales Milestones  
+ Low Double-Digit Royalties on Sales



Exclusive license agreement to use TALEN® technology to develop gene-edited TILs

Undisclosed Development & Sales Milestones  
+ Royalties on Sales



Equity Investor

6.56% ownership in Collectis

As of June 30, 2020



<sup>1</sup>UCART19/ALLO-501 and ALLO-501A are exclusively licensed to Servier and under a joint clinical development program between Servier and Allogene.

# PIPELINE: INNOVATIVE CANCER THERAPIES FOR UNMET NEEDS



Collectis and its partners are also working on a number of other preclinical targets



<sup>1</sup> The ALPHA study targets Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) indications, which are subtypes of HNL

<sup>2</sup> We expect the pivotal phase to be the last clinical phase before commercialization

<sup>3</sup> UCART19/ALLO-501 is exclusively licensed to Servier and under a joint clinical development program between Servier and Allogene

<sup>4</sup> UCARTBCMA/ALLO-715 is exclusively licensed to Allogene

# CLINICAL TRIAL: DESIGN OF PHASE 1 DOSE ESCALATION STUDIES

## Primary Objectives:

**Safety and Identification  
of Optimal Dose**

## Secondary Objectives:

**Efficacy and Correlative  
Studies**

## Dose Escalation:

### Optimal dose definition



# ALLO-501\*: COLLECTIS LICENSED ALLOGENEIC CAR-T

## PHASE 1 dose escalation in R/R Non-Hodgkin Lymphoma




N=22 (safety)  
N=19 (efficacy)

ALPHA Study

### Safety – Primary Objective

0%	Graft vs Host Disease
0%	ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome)
5%	Grade 3 Cytokine Release Syndrome
9%	Grade 3 Infection
5%	Grade 3 Infusion Reaction

### Efficacy – Secondary Objective

63%	Overall Response Rate
37%	Complete Response Rate
75%	ORR in CAR-T naïve patients (N=16)
44%	Complete Response Rate
	Re-dosing one patient with ALLO-501 and ALLO-647 resulted in an ongoing CR

The ALPHA trial utilizes ALLO-647, Allogene's anti-CD52 monoclonal antibody as a part of its lymphodepletion regimen



Data Source: ASCO 2020 Conference Presentation


The ALPHA study targets Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) indications, which are subtypes of NHL.

\* Collectis granted to Servier an expanded exclusive worldwide license to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including rights to ALLO-501. ALLO-501 is under a joint clinical development program between Servier and Allogene. Allogene is the sponsor of the ALLO-501 ALPHA study



# UCART19: FIRST CELLECTIS LICENSED ALLOGENEIC CAR-T

## PHASE 1 dose escalation in R/R ALL



### Safety – Primary Objective

**0%** Grade  $\geq 2$  skin Graft vs Host Disease

**0%** Grade 3-4 neurotoxicity

**14%** Grade 3-4 Cytokine Release Syndrome

### Efficacy – Secondary Objective

**82%** CR/CRi rate with optimal lymphodepletion

**67%** overall CR/CRi rate

**71%** of these patients were MRD-



Re-dosing with UCART19 resulted in cell expansion and MRD- status in 2/3 patients



Peak expansion observed mostly at Day 14

# UCART123 IN ACUTE MYELOID LEUKEMIA

## AML Incidence Rates & Survival Data

19,940

Estimated new cases of AML in the US for 2020


27%

5-year OS in adults




6%

5-year OS in adults >55 years old

### High CD123 expression on malignant cells



### Limited CD123 expression on healthy cells

-  CD123 is expressed >90% on malignant cells in AML
-  Total bone marrow cells ~ 7% CD123 positive
-  Only ~ 1% expresses the antigen at high levels

Also expressed on BPDCN and Hodgkin's lymphoma

### Collectis Trial Recruitment Sites



# UCART22 IN ACUTE LYMPHOBLASTIC LEUKEMIA

## ALL Incidence Rates & Survival Data

6,150

Estimated new cases of ALL in the US for 2020

20%


5-year OS in adults

<6

Months median disease-free survival in R/R pediatric patients

## CD22 Expression in B-cells

Flow cytometric analysis of B-cell differentiation




CD22 is expressed in >95% B-ALL cells

## Treatment potential for CD19-negative patients

Pre-CAR



Post-CAR



Relapses following CD19-directed CAR T-cell therapy can show loss of CD19 antigen but **persistent expression of CD22**



Anti-CD22 CAR T-cells can induce remissions in **CD19 negative B-cells**

## Collectis Trial Recruitment Sites



Weill Cornell  
Medicine

THE UNIVERSITY OF TEXAS  
MD Anderson  
Cancer Center  
Making Cancer History<sup>®</sup>



THE UNIVERSITY OF  
CHICAGO  
MEDICINE

# UCARTCS1 IN MULTIPLE MYELOMA

## MM Incidence Rates & Survival Data

32,270

Estimated new cases of MM in the US for 2020

43-83

Months is median OS for stages 2-3

50%

5-year OS in adults

### High expression on malignant cells

>95%

expression in MM cells

→ CS1 expression is **high**  
**and uniform** on MM cells

### Treatment alternative to BCMA-targeted therapies

- **Many BCMA-targeted cell therapies show relapses** after 12-14 months of treatment
- Elotuzumab, a CS1-targeting antibody, (in combination with lenalidomide and dexamethasone in R/R MM patients) shows:  
**5% CR rate and 45% partial remissions**

### Collectis Trial Recruitment Sites



**Weill Cornell  
Medicine**


THE UNIVERSITY OF TEXAS  
**MD Anderson  
Cancer Center**  
Making Cancer History®



Hackensack  
Meridian Health



# UCARTs – ALLOGENEIC CAR T-CELLS THROUGH PRECISION GENE EDITING



# TALEN® GENE EDITING – ADVANTAGES


## TALEN®:

Driven by **protein/DNA** interactions to work on potential off-site cleavage


Releases DNA ends **accessible to DNA repair mechanisms to perform gene insertions and corrections** through homologous recombination and gene inactivation through non-homologous end joining

Over 20 years of building a **strong patent portfolio** with umbrella patents on gene editing


Our nucleases act like DNA scissors to edit genes at precise target sites:




A) Gene insertion or Knock-In (KI)



B) Gene correction




C) Gene inactivation or Knock-Out (KO)



**>65% Knock-In Efficiency**

**96.8% Knock-Out Efficiency**


# UCART MANUFACTURING



- 8 years of experience in allogeneic CAR-T manufacturing
- Validated gene editing technology for cell manufacturing
- 4 UCART product candidates manufactured so far
- Full QC system in place
- 3 wholly controlled product candidates cleared for 3 clinical trials by the U.S. FDA

# IN-HOUSE MANUFACTURING

## Raw materials



## Clinical & Commercial UCART Product Candidates



**14,000 sq ft. facility**

Production of clinical starting materials

Operational "go-live" targeted in **2020**

**82,000 sq ft. facility**

Production of clinical & commercial UCART product candidates

Operational "go-live" targeted in **2021**



# THE COLLECTIS GROUP



NASDAQ: CLLS

EURONEXT GROWTH: ALCLS

~\$282M\*\* cash as of June 30, 2020

Expected to fund operations into 2022

Based in Paris, France, New York & Raleigh, USA

Patient focused

~68.7%\* ownership



NASDAQ: CLXT

\$35M cash as of June 30, 2020

Cash Runway Extended into Fiscal Year 2022

Based in Minnesota, USA

Consumer focused

High value asset

Gene editing is the link



\* As of June 30, 2020

\*\* \$317M of consolidated cash, cash equivalents, current assets and restricted cash (Collectis + Calyxt)

# MILESTONES

## Proprietary clinical programs

**UCARTCS1:** Phase 1 R/R MM - currently on clinical hold; first patient dosed in Q4 2019

**UCART22:** Phase 1 in R/R ALL ongoing; first patient dosed in Q4 2019

**UCART123:** Phase 1 for R/R AML ongoing; New IND granted by FDA in Q3 2019

## Partnered clinical programs

**UCART19:** Phase 1 in R/R ALL ongoing

**UCART19 (ALLO-501/ALLO-501A):** Phase 1 in R/R NHL ongoing, data presented at ASCO 2020; first patient dosed in H1 2019

**UCARTBCMA (ALLO-715):** Phase 1 in R/R MM ongoing, first patient dosed in H2 2019

## Manufacturing

Ongoing construction of 2 in-house manufacturing plants:

Facility in Paris, France for raw material supply

Facility in Raleigh, North Carolina for GMP, commercial scale UCART manufacturing

# EXPECTED MILESTONES IN 2020

## Clinical programs

Provide interim clinical data on completed dose cohorts for proprietary and partnered programs at relevant scientific conferences

## Manufacturing

Go-live with Paris facility

Construction complete for Raleigh facility



# THANK YOU

Reach us at: [investor@collectis.com](mailto:investor@collectis.com)



Collectis Paris  
8, rue de la Croix Jarry  
75013 Paris – France



Collectis New York  
430 East 29th Street  
10016 New York, NY – USA



Collectis Raleigh  
2500 Sumner Boulevard  
27616 Raleigh, NC – USA